CLAIM CARD
The corpus of contextual other evidence spans a wide range of study designs, populations, and endpoints, reflecting the broad therapeutic interest in rapamycin as a geroprotective compound. The strongest mechanistic signal derives from preclinical mouse studies demonstrating that transient rapamycin treatment can markedly extend lifespan. These preclinical datasets converge on rapamycin as a robust lifespan-extending intervention in rodent models (Phillips 2022b; Bitto 2016; Gkioni 2025).
Evidence grade: exploratory
Contradiction status: none
Publication: f02d4a53-03e5-47ed-9876-75a416e3bd24
Provenance: Derivation Web chain
Citation Support
source_1Moel 2025source_2Gkioni 2025source_3Smiaek 2023source_4Willows 2023source_5Harinath 2025